Evidence map›Paper›PMID 32365132›Full record

ArticlePloS one2020

Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain.

Phillip O Coffin, Christopher Rowe, Natalie Oman, Katie Sinchek, Glenn-Milo Santos, Mark Faul, Rita Bagnulo, Deeqa Mohamed, Eric Vittinghoff

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 4 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2022
    Guideline
  4. Pooled it
  5. Article
  6. Nondual Awareness as a Novel Chronic Pain Relieving Mechanism.Psychology of consciousness (Washington, D.C.) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Phillip O CoffinSan Francisco Department of Public Health, San Francisco, CA, United States of America.ORCID 0000-0002-3891-6570
Christopher RoweSan Francisco Department of Public Health, San Francisco, CA, United States of America.
Natalie OmanSan Francisco Department of Public Health, San Francisco, CA, United States of America.
Katie SinchekSan Francisco Department of Public Health, San Francisco, CA, United States of America.ORCID 0000-0002-7049-8241
Glenn-Milo SantosSan Francisco Department of Public Health, San Francisco, CA, United States of America.
Mark FaulCenters for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Rita BagnuloSan Francisco Department of Public Health, San Francisco, CA, United States of America.
Deeqa MohamedSan Francisco Department of Public Health, San Francisco, CA, United States of America.
Eric VittinghoffUniversity of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0001-8535-0920
San Francisco Department of Public Health · USUniversity of California, San Francisco · USCenters for Disease Control and Prevention · US

Funding

Substance Use and HIV Prevention Research in Minority Communities Training ProgramR25DA028567 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Julia Lechuga, Torsten Brian Neilands · 2009 to 2026
$5.4M
Midcareer K24 Award for Mentoring and Patient-Oriented ResearchK24DA042720 · NIDA · SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH · PI PHILLIP O COFFIN · 2016 to 2026
$1.6M
Substance use outcomes of opioid dose reduction and discontinuationU01CE002793 · CE · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI COFFIN, PHILLIP O · 2016 to 2017
$799k
NCIPC CDC HHS U01 CE002793NIDA NIH HHS K24 DA042720NIDA NIH HHS R25 DA028567
6 · The paper itself

Abstract

backgroundAfter decades of increased opioid pain reliever prescribing, providers are rapidly reducing prescribing. We hypothesized that reduced access to prescribed opioid pain relievers among patients previously reliant upon opioid pain relievers would result in increased illicit opioid use. METHODS AND

findingsWe conducted a retrospective cohort study among 602 publicly insured primary care patients who had been prescribed opioids for chronic non-cancer pain for at least three consecutive months in San Francisco, recruited through convenience sampling. We conducted a historical reconstruction interview and medical chart abstraction focused on illicit substance use and opioid pain reliever prescriptions, respectively, from 2012 through the interview date in 2017-2018. We used a nested-cohort design, in which patients were classified, based on opioid pain reliever dose change, into a series of nested cohorts starting with each follow-up quarter. Using continuation-ratio models, we estimated associations between opioid prescription discontinuation or 30% increase or decrease in dose, relative to no change, and subsequent frequency of heroin and non-prescribed opioid pain reliever use, separately. Models controlled for demographics, clinical and behavioral characteristics, and past use of heroin or non-prescribed opioid pain relievers. A total of 56,372 and 56,484 participant-quarter observations were included from the 597 and 598 participants available for analyses of heroin and non-prescribed opioid pain reliever outcomes, respectively. Participants discontinued from prescribed opioids were more likely to use heroin (Adjusted Odds Ratio (AOR) = 1.57, 95% CI: 1.25-1.97) and non-prescribed opioid pain relievers (AOR = 1.75, 1.45-2.11) more frequently in subsequent quarters compared to participants with unchanged opioid prescriptions. Participants whose opioid pain reliever dose increased were more likely to use heroin more frequently (AOR = 1.67, 1.32-2.12). Results held throughout sensitivity analyses. The main limitations were the observational nature of results and limited generalizability beyond safety-net settings.

conclusionsDiscontinuation of prescribed opioid pain relievers was associated with more frequent non-prescribed opioid pain reliever and heroin use; increased dose was also associated with more frequent heroin use. Clinicians should be aware of these risks in determining pain management approaches.

Indexed as

Illicit DrugsAnalgesics, OpioidChronic PainCohort StudiesDrug PrescriptionsFemaleHeroinHumansMaleMiddle AgedOpioid-Related DisordersPain ManagementPrimary Health CareRetrospective StudiesSan FranciscoAnalgesics, OpioidHeroinIllicit Drugs

Identifiers

PMID32365132
PMCPMC7197848
OpenAlexW3021956938

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.